Timber Pharmaceuticals Presents Late-Breaking Preliminary Results of TMB-001
NYSE American to Suspend Trading Immediately in Timber Pharma
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and...
Leo Pharma plans to acquire dermatology biotech Timber Pharmaceuticals, which is developing a treatment for a rare, genetic skin disease.
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for...
- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc....